Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Lurasidone in Schizophrenia
NCT00088621Phase 2Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Jul 2004
- Primary completion
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lurasidone in schizophrenia, sponsored by Sumitomo Pharma America. Primary endpoint: Number of Subjects With an Adverse Events at 1 year. Started Jul 2004; status: completed.
02
Drugs
lurasidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00088621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00088621.